Pulmatrix Investor Relations Material

Pulmatrix Inc is a U.S.-based clinical-stage biopharmaceutical company focused on developing inhaled therapies for respiratory diseases. The company utilizes its proprietary iSPERSE™ (inhaled Small Particles Easily Respirable and Emitted) technology to formulate dry powder drugs for efficient delivery to the lungs. Pulmatrix's pipeline includes treatments for conditions such as chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and other respiratory disorders. The company is headquartered in Lexington, Massachusetts, and its shares are listed on the NASDAQ.